Lead Product(s) : Prazosin Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules Pharmaceuticals Inc., Receives ANDA Approval for Prazosin Hydrochloride Capsules
Details : Prazosin HCl inhibits the postsynaptic alpha-1 adrenoceptors. This inhibition blocks the vasoconstricting effect of catecholamines on the vessels, leading to peripheral blood vessel dilation.
Product Name : Miniplus-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2021
Lead Product(s) : Prazosin Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prazosin Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Prazosin hydrochloride inhibits the postsynaptic alpha-1 adrenoceptors. This inhibition blocks the vasoconstricting (narrowing) effect of catecholamines (epinephrine and norepinephrine) on the vessels, leading to peripheral blood vessel dilation.
Product Name : Prazosin Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2023
Lead Product(s) : Prazosin Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyproheptadine Hydrochloride,Prazosin Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : ECSOR
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KT-110, a new and innovative approach based on dual receptor targeting. Study evaluates the efficacy, safety and tolerance of KT-110, a combination of 2 molecules protected by a compositional patent, on alcohol consumption in patients suffering from seve...
Product Name : KT-110
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 30, 2021
Lead Product(s) : Cyproheptadine Hydrochloride,Prazosin Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : ECSOR
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
